The further evaluation of IGF2BP1’s role in modulating the expression of such effectors like AURKA will unravel novel avenues to pursue the inhibition of IGF2BP1-mRNA association in combinatorial treatment strategies to improve cancer patient outcome. Here, AURKA is linked to cancer.